Subgroup analyses revealed nuanced differences: ARBs demonstrated superior effects on reducing urinary angiotensinogen and albuminuria in patients with high-normal albuminuria, while aliskiren provided greater reductions in microalbuminuria and systolic blood pressure when used as add-on therapy in type 2 diabetes with uncontrolled hypertension. Here, AGT is linked to hypertensive disorder.